LGH447

DRUG4 trials

Sponsors

Novartis Pharmaceuticals

Conditions

AML and High Risk MDSMultiple MyelomaRelapsed and Refractory Multiple Myeloma

Phase 1

A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

CompletedNCT01456689

Novartis PharmaceuticalsMultiple Myeloma

Start: 2012-04-25End: 2019-06-05Updated: 2020-12-17

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

CompletedNCT02078609

Novartis PharmaceuticalsAML and High Risk MDS

Start: 2014-03-20End: 2019-04-18Updated: 2020-12-17

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

CompletedNCT02144038

Novartis PharmaceuticalsRelapsed and Refractory Multiple Myeloma

Start: 2014-07-23End: 2015-10-28Updated: 2020-12-17

Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies

CompletedNCT02160951

Novartis PharmaceuticalsMultiple Myeloma

Start: 2014-09-30End: 2016-05-31Updated: 2020-12-17

Related Papers

A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma.

2021-02-2714 citations

Concurrent Inhibition of Pim and Akt Pathways with Pim447 and Afuresertib Activates FOXO3a and Depletes c-Myc to Induce Synergistic Cell Death in Multiple Myeloma

Blood2015-12-032 citations